Immuno Oncology Market by 2022- A Global Forecast

World’s one of the biggest and liable market research resource, Research and Markets recently published Immuno-Oncology Market, By Type and By Application- Global Forecast 2022.

Presently, Immuno oncology market has experienced a substantial number of improvements. The level of competition between the companies is accelerating. The biotechnology and pharmaceutical firms are attempting to obtain first mover benefits by introducing new and most effective therapies. This therapy is predicted to…

Kyprolis for Combination use in Patients with Relapsed Multiple Myeloma Gets EC Approval

European Commission (EC) provided marketing authorization for Amgen’s Kyprolis® (carfilzomib) in combo with lenalidomide and dexamethasone for the therapy of adult sufferers with multiple myeloma who have obtained minimum one prior treatment. Kyprolis is the initial irreversible proteasome inhibitor accepted in the European Union (EU) for use in combo treatment of individuals with relapsed multiple myeloma.

Amgen’s Executive vice president of Research…

The Morgan Stanley Global Healthcare Conference: Amgen’s presentation

THOUSAND OAKS, California: The Morgan Stanley Global Healthcare Conference scheduled for Tuesday, Sept. 13, 2011 at the Grand Hyatt in New York City will include a presentation by Amgen (NASDAQ: AMGN) commencing 9:10 AM EST. Senior vice president of North America Commercial Operations at Amgen, Jim Daly, is said to present at the conference. Live audio of the presentation will be made…

AMGEN: Second Quarter of 2011 Witnessed a Revenue Hike of 4% to $4.0 Billion

Amgen’s second quarter product sales for 2011 saw a spike of 8% to $3.9 billion.

The adjusted and GAAP Earnings per Share (EPS) for the second quarter of 2011 were $1.37 and $1.25, respectively. Amgen Announced its First Quarterly Cash Dividend of $0.28 per Share.

2011 Total Revenue and Adjusted EPS Guidance Updated to Upper End of $15.1 Billion to $15.5 Billion and $5.00…